Chimeric peptides against HTLV-1
OwnerMona Kabiri, Mohsen Tafaghodi Piadeh Gheibi +1inventors
InventorsMona Kabiri, Mohsen Tafaghodi Piadeh Gheibi, Mojtaba Sankian
Life of this patent
Estimating the term…
Abstract
A method of immunizing against HTLV-1 is disclosed. The method may include preparing a DNA sequence corresponding to a chimeric peptide which may have immunogenic epitopes of HTLV-1. These epitopes can include a Tax epitope, a gp21 epitope, a gp46 epitope, and/or a gag epitope. The method also includes production of the chimeric peptide using the DNA sequence and purifying the produced chimeric peptide. The purified chimeric peptide can be employed for immunization against HTLV-1.
Claims10
A method for inducing an immune response against human T-lymphotropic virus type 1 (HTLV-1), the method comprising:
- preparing a DNA sequence, the DNA sequence encoding a chimeric peptide with immunogenic epitopes, the immunogenic epitopes including a HTLV-1 Tax epitope, a HTLV-1 gp21 epitope, a HTLV-1 gp46 epitope, and a HTLV-1 gag epitope, the chimeric peptide comprising SEQ ID No. 2 or SEQ ID No. 4;
- producing the chimeric peptide using the DNA sequence;
- forming a purified chimeric peptide by purifying the produced chimeric peptide;
- and
- inducing an immune response against HTLV-1 using the purified chimeric peptide.
A method for inducing an immune response against human T-lymphotropic virus type 1 (HTLV-1), the method comprising:
- preparing a DNA sequence, the DNA sequence encoding a chimeric peptide with immunogenic epitopes, the immunogenic epitopes including a HTLV-1 Tax epitope, a HTLV-1 gp21 epitope, a HTLV-1 gp46 epitope, and a HTLV-1 gag epitope, the DNA sequence comprising SEQ ID No. 1 or SEQ ID No. 3;
- producing the chimeric peptide using the DNA sequence;
- forming a purified chimeric peptide by purifying the produced chimeric peptide;
- and
- inducing an immune response against HTLV-1 using the purified chimeric peptide.
Dependencies are inferred from the claim text.